tbuckley/cabot-search huggingface dataset:
Stroke Etiologic Classification—Moving From Prediction to Precision
Authors: Mitchell S. V. Elkind
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Hh/IGF-1R/PI3K/Akt/MRP1 Pathway Induce Refractory Acute Myeloid Leukemia and Its Targeting Therpy
Authors: Kaikai Huang, Bingjie Ding, Qingxiu Zhong, Xuejie Jiang, Xiaodong Li, Zhixiang Wang, Fan Yi Meng
Journal: Blood (2014)
Activation of protease-activated receptor 4 of mast cells could downregulate proinflammatory cytokines in irritable bowel syndrome
Authors: Shuhong An, Guofang Zong, Zhaojin Wang, Juan Shi, Hui Du, Jiangong Hu
Journal: Gut (2017)

We read with interest the article by Wouters et al 1 on mast cells (MCs) that dominate the mucosal inflammatory infiltrate in the intestine of functional GI disorders (FGIDs). Protease-activated receptor 4 (PAR4) is extensively expressed in MCs in allergic inflammation2 and may mediate an antinociceptive effect in gut visceral hyperalgesia.3 We wish to report the potential influence of PAR4 activation on the production of cytokines from MCs that might regulate sensitisation and subsequent heightened pain behaviour in FGIDs.4 ,5

Immunoreactivity for tryptase and PAR4 was analysed in the colonic mucosa of 21 patients with IBS with diarrhoea (IBS-D) and 16 healthy controls (figure 1A, B). Numbers of MCs were obtained by counting tryptase-immunoreactive cells. There were substantial increases in the numbers of both tryptase and PAR4-positive cells seen in IBS-D colonic mucosa compared with those in healthy controls. Double labelling showed that PAR4 is highly expressed in tryptase-staining MCs in the colon of patients with IBS-D.



Figure 1 
Immunohistochemical staining for tryptase (mast cells (MCs)) and protease-activated receptor 4 (PAR4) in colon sections of patients with IBS with diarrhoea (IBS-D), and the effect of PAR4 on interleukin (IL)-1β expression in bone marrow MCs (BMMCs). (A) Representative immunostaining for tryptase and PAR4 is shown. Colonic sections were incubated with antibodies against tryptase (Abcam) and PAR4 (Alomone Labs), and counterstained with toluidine blue. Scale bar represents 100 μm. (B) Graph showing the …
Micafungin Is Extremely Effective Against Fungal Infections Complicating Hematological Malignancies: Report of a Multicenter Study by N-FISH (Niigata Fungal Infection Study Group in Hematology).
Authors: Sadao Aoki, Jun Takizawa, Yoshinobu Seki, Kazue Takai, Koji Nikkuni, Souichi Maruyama, Nobuhiko Nomoto, Nobuhiro Tsukada, Yoshifusa Aizawa
Journal: Blood (2005)
The Histone Deacetylase Inhibitor Vorinostat (SAHA) Induces Apoptosis and Cell Cycle Arrest in Hodgkin Lymphoma (HL) Cell Lines by Altering Several Survival Signaling Pathways and Synergizes with Doxorubicin, Gemcitabine and Bortezomib.
Authors: Georgios V. Georgakis, Victor Y. Yazbeck, Yang Li, Anas Younes
Journal: Blood (2006)
Erratum to: Methylome Evolution in plants
Authors: Amaryllis Vidalis, Daniel Živković, René Wardenaar, David Roquis, Aurélien Tellier, Frank Johannes
Journal: Genome biology (2017)

After publication of this article [1] we noticed that the centromere of Chromosome 3 was missing from Fig. 4a, and that the Fig. 4e y-axis should read 'CG meth.Div.W-Acc.'.The y-axis of the barplot in Fig. 5a should read 'Number of cytosines'.The corrected Figs. 4 and 5 are shown below.
Mechanisms of Platelet Activation by Antithymocyte Globulin (ATG).
Authors: Florian Langer, Francis A. Ayuk, Ali Amirkhosravi, Brigitte Spath, Todd Meyer, Theresa Robson, Liza Robles, Guy Marx, Simon D. Lytton, Katharina Holstein, Barbara Eifrig, Carsten Bokemeyer, Axel R. Zander, Nicolaus Kroeger
Journal: Blood (2006)
Gas1 and Kif27 Genes Are Strongly up-Regulated Biomarkers of Hedgehog Inhibition (PF-04449913) on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients
Authors: Viviana Guadagnuolo, Cristina Papayannidis, Ilaria Iacobucci, Sandra Durante, Carolina Terragna, Emanuela Ottaviani, Maria Chiara Abbenante, Federica Cattina, Simona Soverini, Barbara Lama, Lucia Toni, Wendy J. Levin, Rachel Courtney, Carmen Baldazzi, Antonio Curti, Michele Baccarani, Catriona Jamieson, Jorge E. Cortes, Vivian Oehler, Karen McLachlan, Todd Van Arsdale, Giovanni Martinelli
Journal: Blood (2011)
A microRNA Expression-Based Model Predicts Event Free Survival in Pediatric Acute Myeloid Leukemia
Authors: Emilia L. Lim, Diane L. Trinh, Rhonda E. Ries, Jim Wang, Yussanne Ma, James Topham, Maya D. Hughes, Erin Pleasance, Andrew J. Mungall, Richard Moore, Yongjun Zhao, E. Anders Kolb, Alan S. Gamis, Daniela S. Gerhard, Todd A. Alonzo, Soheil Meshinchi, Marco A. Marra
Journal: Blood (2016)
Oncogenic role of microRNA‐155 in mycosis fungoides: an <i>in vitro</i> and xenograft mouse model study
Authors: L. Moyal, S. Yehezkel, B. Gorovitz, A. Keren, A. Gilhar, I. Lubin, S. Sherman, E. Hodak
Journal: British Journal of Dermatology (2017)

MicroRNA (miR)‐155 contributes to the proliferation of mycosis fungoides (MF) in vitro and is upregulated in tumours of MF compared with early MF lesions. To investigate the contribution of miR‐155 to the cancerous phenotype and drug resistance of MF/Sézary cell lines. miR‐155 was inhibited in MF cell lines (MyLa and MJ) by transduction of miRZip anti‐miR‐155, and overexpressed in Hut78 cells by transduction of miRVec‐miR‐155; empty plasmids served as controls. Cells were analysed for response to inducers of apoptosis and cell‐cycle arrest, using fluorescence‐activated cell sorting. Transduced MyLa cells were subcutaneously injected into severe combined immunodeficient mice, and tumours were analysed immunohistochemically and for final size. MyLa and MJ cells expressed a high level of miR‐155; Hut78 cells expressed a low level. MF cell lines stably expressing miR‐155 inhibitor showed increased G2/M arrest in response to N‐p‐tolyl‐2‐(3,4,5‐trimethoxyphenyl quinazolin‐4‐amine) (SL111), an inducer of cell‐cycle arrest, followed by increased apoptosis. Additionally, they showed increased apoptosis in response to suberoylanilide hydroxamic acid (SAHA). Tumours formed in mice from injected anti‐miR‐155‐expressing MyLa cells had a significantly lower volume and higher occurrence of apoptosis than controls. Stable overexpression of miR‐155 in Hut78 cells had no effect. Oncogenic miR‐155 appears to contribute to the cancerous phenotype of MyLa and MJ cells, but not of Hut78 cells, by interrupting activation of the G2/M checkpoint in response to SL111, and decreasing apoptosis in response to SL111 and SAHA, thereby facilitating tumour growth. These findings have implications for the potential development of novel therapeutic modalities for MF incorporating miR‐155 inhibitors.
A pilot study of temsirolimus and body composition.
Authors: Heloisa Veasey Rodrigues, Henrique Afonseca Parsons, Filip Janku, Aung Naing, Jennifer J. Wheler, Apostolia Maria Tsimberidou, Razelle Kurzrock
Journal: Journal of Clinical Oncology (2012)

e13534 Background: Body weight and composition play a role in cancer etiology, prognosis and treatment response. Temsirolimus is an mTor inhibitor that can cause weight loss. Therefore, we analyzed weight, body composition changes and outcome in patients treated with temsirolimus. Methods: Sixteen patients with advanced solid tumors who participated in a trial with temsirolimus were studied; body composition was evaluated utilizing computerized tomography (CT) images. Sarcopenia was defined (CT-based criteria) as skeletal muscle index lower than 38.5cm 2 /m 2 for women and 52.4cm 2 /m 2 for men. Results: Five of 16 patients (31%) were men; median age, 60 years. There were no overall significant changes in weight, body mass index and body composition parameters after two months. Baseline sarcopenia was present in 44% (7/16) of patients. Fatigue, anemia, hyperglycemia and hyperlipidemia were common. Baseline sarcopenia and body composition did not correlate with worse toxicity or treatment outcome. However, there was significantly greater loss in the composite body fat content for patients with grade 3 or 4 toxicities versus those with grade 1 and 2 toxicities (p=0.007). There was a trend towards loss of body fat content for progressors versus those with stable disease/partial response (SD/PR)(p=0.08), and loss of body muscle content for the SD/PR group versus progressors (p=0.07). Conclusions: Patients with higher grade toxicities had a greater loss of body fat content, and patients with SD/PR showed a trend to loss of body muscle content as compared to those with progression, suggesting an end-organ metabolic effect of temsirolimus.
Isocitrate Dehydrogenase Gene Mutations In Elderly Patients with Acute Myeloid Leukemia (AML) and Outcome After Treatment with All-Trans Retinoic Acid: A Study of the German-Austrian AML Study Group (AMSLG)
Authors: Peter Paschka, Richard F. Schlenk, Mariam Ibañez, Alexandra Kagias, Lars Bullinger, Verena I. Gaidzik, Daniela Späth, Heinz A. Horst, Gerhard Held, Martin Bentz, Stephan Kremers, Richard Greil, Mohammed Wattad, Wolfram Brugger, Volker Runde, Aruna Raghavachar, Hans-Guenter Derigs, Heinrich Kirchen, Hartmut Döhner, Konstanze Döhner
Journal: Blood (2010)
Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib.
Authors: Allen S. Yang, Anand Jillella, Carole B. Miller, Luke P. Akard, Daniel J. DeAngelo, Stuart L. Goldberg, Denise Williams, Jerald P. Radich
Journal: Blood (2009)
Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)
Authors: Takashi Kumagai, Chiaki Nakaseko, Kaichi Nishiwaki, Chikashi Yoshida, Kazuteru Ohashi, Naoki Takezako, Hina Takano, Yasuji Kouzai, Tadashi Murase, Kosei Matsue, Satoshi Morita, Junichi Sakamoto, Hisashi Wakita, Hisashi Sakamaki, Koiti Inokuchi
Journal: Blood (2016)
Locally advanced adenocarcinoma and adenosquamous carcinoma of the cervix compared to squamous cell carcinoma of the cervix in Gynecologic Oncology Group trials of chemoradiation.
Authors: Peter Graham Rose, James Java, Charles W. Whitney, Henry Keys, Rachael Lanciano, Gillian Thomas
Journal: Journal of Clinical Oncology (2013)

5530 Background: Conflicting results have been reported for adeno- and adenosquamous carcinomas the cervix with respect to their response to therapy and prognosis. Adeno- and adenosquamous carcinoma comprise the majority of non-squamous carcinomas of the cervix enrolled in GOG trials of chemoradiation. Methods: Adeno- and adenosquamous cervical carcinomas were retrospectively studied and compared to squamous cell carcinomas in GOG trials of chemoradiation. Results: Among 1672 patients enrolled in clinical trials of chemoradiation, 182 adeno- and adenosquamous carcinomas were identified (10.8%). A higher percentage of adeno- and adenosquamous carcinomas were stage IB (27% versus 20%) and fewer were stage IIIB (21.4% versus 28.6%). The mean tumor size was larger for squamous than adeno- and adenosquamous carcinomas, but adeno- and adenosquamous carcinomas were more often poorly differentiated (46.2% versus 26.8%). Among patients that received cis-platinum during radiation therapy, 843 with squamous cell carcinoma were compared to 112 with adeno- or adenosquamous carcinoma for overall survival, with no significant difference in risk of death (p=0.472). However, among patients that did not receive cis-platinum, 647 with squamous cell carcinoma and 70 with adeno- or adenosquamous carcinoma, there was a slightly higher risk of death for the adeno- or adenosquamous group (p=0.049). Adverse effects to treatment were similar across histologies. Conclusions: Patients with adeno- and adenosquamous carcinomas of the cervix have worse overall survival when treated with radiation alone, but have progression-free and overall survival similar to patients with squamous cell carcinomas of the cervix when treated with cis-platinum based chemoradiation.
LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases
Authors: Guilin Qiao, Jianzhong Qin, Nicholas Kunda, Jed F. Calata, Dolores L. Mahmud, Peter Gann, Yang-Xin Fu, Steven A. Rosenberg, Bellur S. Prabhakar, Ajay V. Maker
Journal: Cancer Research (2017)

Abstract The majority of patients with colon cancer will develop advanced disease, with the liver being the most common site of metastatic disease. Patients with increased numbers of tumor-infiltrating lymphocytes in primary colon tumors and liver metastases have improved outcomes. However, the molecular factors that could empower antitumor immune responses in this setting remain to be elucidated. We reported that the immunostimulatory cytokine LIGHT (TNFSF14) in the microenvironment of colon cancer metastases associates with improved patient survival, and here we demonstrate in an immunocompetent murine model that colon tumors expressing LIGHT stimulate lymphocyte proliferation and tumor cell–specific antitumor immune responses. In this model, increasing LIGHT expression in the microenvironment of either primary tumors or liver metastases triggered regression of established tumors and slowed the growth of liver metastases, driven by cytotoxic T-lymphocyte–mediated antitumor immunity. These responses corresponded with significant increases in tumor-infiltrating lymphocytes and increased expression of lymphocyte-homing signals in the metastatic tumors. Furthermore, we demonstrated evidence of durable tumor-specific antitumor immunity. In conclusion, increasing LIGHT expression increased T-cell proliferation, activation, and infiltration, resulting in enhanced tumor-specific immune-mediated tumor regressions in primary tumors and colorectal liver metastases. Mechanisms to increase LIGHT in the colon cancer microenvironment warrant further investigation and hold promise as an immunotherapeutic strategy. Cancer Res; 77(8); 1880–91. ©2017 AACR.
Prognostic value of deep sequencing method for minimal residual disease (MRD) detection in multiple myeloma.
Authors: Joaquin Martinez-Lopez, Ramon Garcia-Sanz, Francois Pepin, Rosa Ayala, Maria Angeles Montalban, Bruno Paiva, Li Weng, Santiago Barrio, Laura Montejano, Immaculada Rapado, Rafael Martinez, Maria Jesus Blachard, Pedro Sanchez-Godoy, Joan Blade, Jesùs F. San-Miguel, Malek Faham, Juan José Lahuerta
Journal: Journal of Clinical Oncology (2013)

8511 Background: Most multiple myeloma (MM) patients will relapse due to persistence of residual tumor cells, or MRD. We compared the prognostic value of traditional response criteria and MRD measurement by a sequencing-based method, LymphoSIGHT, and multiparameter flow cytometry (MFC) in a cohort of 68 uniformly-treated MM patients from the Spanish Myeloma Group trials. Methods: Bone marrow samples were obtained from 68 patients at diagnostic and post-treatment time points on GEM clinical trials (GEM00 and GEM05). All patients were in CR or VGPR at the post-treatment time point. Using sequencing, we identified clonal rearrangements of immunoglobulin (IGH-VDJ, IGH-DJ, and IGK) genes in diagnostic samples. We assessed MRD in follow-up samples, analyzed concordance between sequencing and MFC MRD results, and compared the prognostic value of each method with traditional response criteria. Results: The sequencing assay detected a myeloma-specific gene rearrangement in diagnostic samples from 59 of 68 (87%) patients. We tested MRD in follow-up time points in 56 of the 59 patients. We observed high correlation between MFC and sequencing MRD results (r 2 =0.86), with MFC underestimating the myeloma burden (Slope=0.4). Of the 56 patients, 45 were positive by sequencing at MRD levels of 10 -5 or higher and 11 were MRD negative. There was significantly improved overall survival (OS) in the MRD negative group versus the MRD positive group (median not reached vs. 86 mos, p=0.026). Similar differences were found in progression free survival. When limiting the analysis to the 35 patients in conventional CR, 24 of 35 patients were positive by sequencing at MRD levels at 10 -5 and higher and 10 were MRD negative. There was significantly improved OS in the MRD negative group versus the MRD positive group (median not reached vs. 80.92 mos, p=0.041). Conclusions: Our data shows high correlation between MFC and sequencing MRD levels in MM patients. For patients in CR by traditional response criteria, the presence or absence of MRD by sequencing delineated 2 groups of patients with significantly different OS. MRD negativity by sequencing may be a better prognostic indicator than CR by traditional response criteria.
US immunization programs would be gutted under Republican health bill, experts say
Authors: Owen Dyer
Journal: BMJ (2017)

The Republican leadership’s proposed American Health Care Act, announced Monday 6 March,1 threatens to cripple the immunization program of the Centers for Disease Control and Prevention (CDC) by stripping away most of its funding.

It will also remove hundreds of millions in funding from states’ vaccination efforts, heart disease screening, and programs to reduce hospital infections and antimicrobial resistance. And it will leave no money for the CDC’s blood lead surveillance and exposure reduction program in 29 states.

The act would end the federal Prevention and Public Health Fund from October next year, with no suggestion of a replacement. This fund, established by the Affordable Care Act and providing roughly $1bn a year, has become a key part of CDC funding, especially in the agency’s immunization programs.

Rumors last week that the fund was endangered prompted more than …
Continuous High-Dose Idarubicin and Busulfan As Conditioning Regimen for Chinese Patients with Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation
Authors: Hong Ming, Sixuan Qian, Liu Peng, Wu Hanxin, Qiu Hongxia, Lu Hua, Zhang Sujiang, Xu Wei
Journal: Blood (2012)
Abstract P3-04-12: Both spliced and unspliced XBP1 regulates breast cancer cell fate response to antiestrogen via NFkappaB signaling
Authors: R Clarke, R Hu, A Warri, L Jin, A Zwart, R Riggins, H-b Fang
Journal: Cancer Research (2017)

Abstract Unfolded protein response (UPR), a stress-induced survival mechanism, may be used by cancer cells to avoid cell death. Antiestrogen therapy, widely applied in the treatment of estrogen receptor-positive (ER+) breast cancer, induces endoplasmic reticulum stress (EnR stress) that leads to activation of each of the three arms of the UPR. One critical prosurvival activator that is regulated by two arms of the UPR is the transcription factor X-box binding protein 1 (XBP1). XBP1 exists in two isoforms, the transcriptionally inactive unspliced XBP1(U) and the spliced, active XBP1(S). Overexpression of XBP1(S) confers estrogen independence and antiestrogen resistance in ER+ breast cancer cells and XBP1(S) expression correlates with poor clinical responsiveness to Tamoxifen in ER+ breast tumors. However, the underlying signaling mechanisms regulated by XBP1, which may mediate its effects on antiestrogen resistance, are unknown. We show that depletion of endogenous XBP-1 by siRNA increases apoptosis, decreases autophagy, requires down-regulation of p65/RelA, a component of the pro-survival NFκB complex. Using novel spliced and non-spliceable forms of XBP1, we show that XBP1(U) and XBP1(S) both regulate NFκB activity via ERα signaling in breast cancer cells. XBP1(S), but not XBP1(U), also can regulate p65/RelA expression independent of ERα. Antiestrogen resistance as conferred by XBP1 overexpression in MCF-7 cells requires the activation of NFκB signaling; inhibition of NFκB signaling by either the small molecule NFκB inhibitor Parthenolide or p65/RelA siRNA sensitizes XBP1 overexpressing cells to Tamoxifen. The activation of XBP1 and the downstream NFκB signaling is likely to contribute to the TMEM33 overepxression induced apoptosis, as both NFκB signaling and XBP1(S) are elevated in TMEM33 overexpressed MCF7 cells. Thus, we have identified a critical regulatory link between the UPR/XBP1 pathway and pro-survival NFκB signaling that is a major contributor to endocrine responsiveness in ER positive breast cancer. Citation Format: Clarke R, Hu R, Warri A, Jin L, Zwart A, Riggins R, Fang H-b. Both spliced and unspliced XBP1 regulates breast cancer cell fate response to antiestrogen via NFkappaB signaling [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-04-12.
Optimal Thalassemia Free Survival and Minimal Regimen Related Toxicity in 50 Consecutive Transplants of High Risk Beta Thalassemia Pediatric Patients Using Myelablative Therapy with Intravenous Busulphan.
Authors: Sarah Marktel, Robert Chiesa, Barbara Cappelli, Tito Roccia, Ilaria Frugnoli, Anna Noè, Erika Biral, Roberto Crocchiolo, Costanza Evangelio, Marco Fossati, Sara Napolitano, Clara Soliman, Laura Cursi, Federica Cattaneo, Laura Zito, Rossana Fiori, Katharina Fleischhauer, Roberto Miniero, Fabio Ciceri, Maria Grazia Roncarolo
Journal: Blood (2008)
Increased Gene Expression of Histone Deacetylases In Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
Authors: Vibe Skov, Thomas Stauffer Larsen, Mads Thomassen, Caroline Riley, Morten Krogh Jensen, Ole Weis Bjerrum, Torben A Kruse, Hans Carl Hasselbalch
Journal: Blood (2010)